For a Nonkilling World let us Confront the Super El Nino Threat of 451000 deaths

 The looming threat of Super El Niño in an exceptionally severe phase of the El Niño–Southern Oscillation (ENSO) climate cycle as to be confronted by humanity before it is too late. Indeed, unlike the standard El Niño events where equatorial Pacific waters warm moderately, a "super" event sees sea surface temperatures spike significantly higher often above 2 degrees Celsius above baseline—triggering widespread and intense climate anomalies. A landmark study from researchers at the Climate Impact Lab (led by the University of Chicago and UC Berkeley) estimates that extreme thermal stress from the Super El Niño could cause 451,000 excess heat deaths globally between late 2026 and early 2027.

The Key Drivers Behind the Projections are:

• A Surge in "Extremely Hot" Days
• Severe Imbalance in the Global South
• A "Postcard from the Future"
• Compounding Secondary Crises

For a Nonkilling World we need Actionable Prevention and Mitigation

Yes, the researchers stress that these data points are projections, not inevitable outcomes. By identifying localized risk factors in advance, governments, civic bodies, and leaders can enact targeted interventions:

1. In the context of a "Nonkilling World," where the primary goal is the measurable reduction and eventual elimination of the intent and act of killing, "Actionable Prevention and Mitigation" involves a shift from reactive to proactive, data-driven, and community-centered strategies. It means not just condemning violence but implementing specific, practical measures that remove the triggers and reduce the physical capacity for killing to occur.

Here is an expansion and explanation of how this translates into the four key areas you've identified, and how they apply to the looming climate-health crisis from a Super El Niño.

What can be the Actionable Prevention vs. Mitigation

• Actionable Prevention: These are strategies designed to stop the event or risk from occurring in the first place or to prevent the initial conditions that would lead to a loss of life. In a nonkilling context, it means creating social, physical, and infrastructure barriers so that lethal conditions (like extreme heat or resource conflict) do not even emerge.
• Actionable Mitigation: This accepts that a hazardous event (like a Super El Niño) is unavoidable and focuses on reducing the severity of its impact. Mitigation strategies are "damage control"—concrete, pre-planned actions to limit the number of lives lost and the scope of suffering once the event is underway.

Let us Expand the Four Key Intervention Areas as under:

For humanity to navigate crises like a Super El Niño through a nonkilling lens, these four pillars require localized, specific, and resourced action.

1. Urban Infrastructure Adaptation: Breaking the "Heat Island" Effect

The Challenge: Cities are significantly warmer than surrounding rural areas because concrete, asphalt, and dark roofs absorb and radiate heat (the urban heat island effect). Without intervention, a Super El Niño's extreme heat becomes magnified, leading to a high volume of heatstroke and death.

Nonkilling Strategy: Break the physical conditions of lethality.

• Explanation: Urban planners must shift from standard aesthetic or purely functional design to "heat-resilient and life-affirming" infrastructure.
• Actionable Prevention & Mitigation Steps:
• Green Cooling Networks: Implement massive urban tree-planting initiatives and prioritize "green roofs" (covering roofs with vegetation) to provide natural shade and cool the air through evapotranspiration.
• Cool Surfaces: Launch programs to paint roofs, roads, and parking lots with reflective "cool materials" that significantly reduce heat a
• Expanding Public Cooling Facilities: Map and establish accessible cooling centers (in libraries, community centers, schools) that operate 24/7 during heat emergencies, with free transport options for vulnerable residents.

2. Workplace Protections: To Prevent"Economic Death"

The Challenge: During a crisis like Super El Niño, agricultural workers, construction workers, delivery personnel, and other outdoor laborers are forced to choose between a dangerous loss of income or risking death from heat stress. This economic pressure effectively becomes a lethal coercion.

Nonkilling Strategy: Decouple livelihood from physical danger.

• Explanation: Governments and labor bodies must recognize that forcing labor in lethal conditions is an indirect act of killing. Proactive economic and regulatory mitigation must protect workers.
• Actionable Prevention & Mitigation Steps:
• Mandatory Heat-Safety Protocols: Codify legally binding protocols that stop work or force extensive, paid rest breaks when a predetermined "wet-bulb globe temperature" (a precise measure of heat stress) is reached.
• Flexible Hours: Implement "early start" or "night shift" options for all outdoor labor to completely bypass the hottest parts of the day.
• Income Protections: Establish "heat disaster" funds or specific insurance mechanisms to provide partial or full wage replacement for low-income outdoor workers on mandatory "no-work" days.

3. Healthcare Preparedness: Escalating Capacity Before the Surge

The Challenge: Extreme heat spikes lead to a cascading surge of acute emergencies (heatstroke, myocardial infarction, acute renal failure, exacerbated respiratory conditions). Healthcare systems in many of the hardest-hit regions (e.g., the Sahel, Southeast Asia) are already operating close to capacity and can be completely overwhelmed. A lack of preparedness leads to preventable deaths from systemic failure.

Nonkilling Strategy: Build a "Life-Saving Escalation" capability.

• Explanation: Healthcare systems must pre-emptively prepare to scale operations to prevent the tipping point where they can no longer offer life-saving care.
• Actionable Prevention & Mitigation Steps:
• Pre-emptive Resourcing: Pre-position critical heat-related supplies—such as IV fluids for rehydration, rapid-cooling devices (e.g., ice-immersion tubs), and specialized heat-impact diagnostic tools—in areas identified as high-risk.
• Scaling Primary Care Staffing: Implement localized primary care "surge staffing" plans, calling upon medical reservists or re-assigning non-critical staff to triage and treat early-stage heat issues before they become life-threatening.
• Heat-Specific Clinical Training: Mandate training for all medical staff on the latest clinical guidelines for diagnosing, treating, and rapidly cooling patients with heatstroke and heat exhaustion.

4. Early Warning Systems: Providing a "Head Start" for Life

The Challenge: Many heatwaves or severe weather disasters lead to mass casualties because vulnerable populations are caught completely off guard. Without specific, timely, and trusted information, people cannot take life-saving actions.

Nonkilling Strategy can ensure that information empowers survival:

• Explanation: A nonkilling world requires a commitment to hyper-localized, trusted communication. It's not just about a weather report, but about giving citizens the tools and warnings necessary to protect themselves.
• Actionable Prevention & Mitigation Steps:
• Rapid-Response Community Alerts: Develop and deploy multi-channel early warning systems (utilizing SMS, social media, radio, and even door-to-door community workers) that send alerts days ahead of an anticipated extreme heat event.
• Actionable Guidance: Do not just announce high temperatures. Every alert must include clear, concise, actionable advice on what to do (e.g., "Drink an extra 2 liters of water," "Check on your elderly neighbor," "Avoid outdoors between 12-4 PM").
• Localized Heat Indices: Instead of generic city-wide temperatures, utilize and communicate localized heat indices (which incorporate humidity) and provide neighborhood-specific risk maps so that residents understand the exact danger in their immediate area.

References & Further Reading

• Primary Research Report: Climate Impact Lab Projections on Super El Niño Mortality
• Media Coverage & Context: The Print: Super El Niño Projected to Cause 450,000 Heat Deaths
• Video Deep Dive: Youtube: Scientists Predict 450,000 Extra Deaths As El Niño Breaks Records

International Nonkilling Day 28th June 2028

  

As the Chairperson of the Centre for Global Nonkilling (CGNK in special consultative status of UN) at Hawaii,  it was a privilege to Preside the virtual Colloquium on International Nonkilling Day 28 June. Global leaders, scholars, and peace activists gathered for a powerful international webinar celebrating the 96th birth anniversary of Dr. Glenn D. Paige, the visionary founder and Chairperson of the Center for Global Nonkilling (CGNK). Centered on the theme "Rejuvenating the Nonkilling Spirit: From Cultural Unity to a Nonkilling Future,", this landmark event was brought an extraordinary lineup of global leaders dedicated to peace, academic research, and grassroots activism.

hashtag

In affirmation of the Global Nonkilling Spirit, I began with a humble and sacred  invocation:

In remembrance of all who have been killed,
of all the killers, and of all who have not killed,
and of all who have worked to end killing;
guided by the Global Nonkilling Spirit—ta
ught by faiths and found within—
we pledge ourselves and call upon all to work toward the measurable goal of a killing-free world,
with infinite creativity in reverence for life.
We call upon leaders and people everywhere to affirm this spirit
and to become centers of Global Nonkilling,
advancing a world free from killing.

---

This year’s theme, “Rejuvenating the Nonkilling Spirit,” calls upon us to transcend boundaries of belief, race, creed, and identity, and to elevate our collective consciousness in sacred reverence for all life.

---

In Remembrance

We paid our heartfelt tribute to cherished members of our nonkilling fraternity who are no longer with us:

• Prof. Francisco Gomes de Matos (1933–2025) — our beloved Nonkilling Poet Laureate, whose seminal work Nurturing Nonkilling: A Poetic Plantation continues to inspire humanity toward peace through language.
• Lou Ann Ha’aheo Guanson,
• Dr. Chaiwat Satha-Anand,
• Thomas Fee,

and other stalwarts including:

• Dr. A. T. Ariyaratne
• Prof. Johan Galtung
• Dr. David Krieger

Their enduring legacies remind us of a world envisioned in Prof. Gomes de Matos’s words:
“Peace. Nonviolence. Nonkilling — they preserve, protect, and prioritize life on Earth.”

In a world increasingly challenged by violence and killings —whether through war, terror, genocide, or ecocide—I made a call for more insights and engagement as these are invaluable for mass campaign towards the goal of a Nonkilling world.

---

CGNK Initiatives for 2026–2027

• Nonkilling Calendar of Events released on 28th June 2028
• New CGNK Centres now functional to be registered in Manila, Thailand and Australia
• No Guns No Ownerships for a Nonkilling World Campaign attached
• Appeal to UN Secretary General to end Middle East Conflict as attached
• Nonkilling Peace Academy Courses launched in Philippines
• Peace Nonviolent Mentor Mentee Project as attached
• Youth Nonkilling Poster Competition in select cities
• CGNK Thinkers’ Forum – fostering dialogue among young minds
• Book Distribution & Author Engagement Program in Bhopal
• Global Ambassadors for Nonkilling Peace (GANP) call for nominations
• Collaborations with international organizations and UN programs
• Creative and cultural outreach including competitions, workshops, and media engagement
• Nonkilling Enrichment Program for families and communities
• Proposed International Conference with the AUAP on Dec 4th and 5th at Bangkok Thailand.
  

These initiatives aim to nurture values of nonkilling compassion, leadership, empathy, and human dignity.

---

A Reflection for the Day Penned by me,

Let Us Uphold the Nonkilling Flame

Let us reaffirm the Nonkilling way,
A path of virtue where no lives are lost.
With steadfast hearts and minds aligned,
We rise above all fear and cost.

Through wisdom shared and compassion deep,
We shape a world both just and fair.
Guided by light and conscious thought,
We nurture hope with tender care.

Planting kindness in every mind,
A gentler, wiser world we bring—
Where every life is held as sacred,
And love transcends all suffering.

Opening the formal program, I on behalf of the Centre for Global Nonkilling paid a solemn tribute to the departed souls of the global nonkilling fraternity, specifically acknowledging the lasting legacies and contributions of Professor Francisco Gomes de Matos (1933–2025), Dr. Chaiwath Satha-Anand, Thomas Fee, Dr. A. T. Ariyaratne, Professor Johan Galtung, Dr. David Krieger, and Lou Ann Ha’aheo Guanson.

The highly distinguished Panelists & Speakers Included:
Dr. N. Radhakrishnan – Officially launched and released the new global Nonkilling Calendar for 2026.
Prof. P.B. Sharma – Addressed pressing climate challenges, ethical living, and leading the way with university-led nonkilling initiatives.
Dr. John Bellavance – Spoke on the intersection of physical wellness and the political "Headwind" philosophy to unify global governance.
Dr. Bill (Balwant) Bhaneja – Discussed advancing the nonkilling paradigm and expanding the vital reach of the Caribbean Center.
Dr. Joám Evans Pim – Highlighted driving forward CGNK’s core institutional pillars: Research, Education, and Action.
Christoph Barbey – Shared insights on UN representation, human rights text inclusion, and critical suicide decriminalization campaigns.
Dr. Evelin Lindner – Expounded on "Dignism"—the crucial framework of preventing humiliation to build life-affirming governance systems.
Dr. Roland Joseph– Demonstrated how French philosopher Edgar Morin’s concept of complex thinking mirrors Glenn Paige’s paradigm. He emphasized that because killing is a complex issue spanning politics, psychology, and public health, we must reject fragmented thinking and act collectively across CGNK’s global multi-disciplinary network to protect human life.
Dr. Vidya Jain – Advocated for utilizing core Gandhian principles to redesign individual consciousness and empower the youth.
Dr. Leslie Sponsel (via video presentation) – Explored the innate, deep-rooted universality of nonkilling already existing within human culture.

In her closing address Dr Katyayani Singh mentioned that the path to global peace requires a profound paradigm shift—moving from theory to a lived, global reality as she thanked everyone of the eminent speakers and participants from across the globe who were present.

Artificial Intelligence and the Future of Drug Discovery

The Future of Drug Discovery

Artificial intelligence is making the future of drug discovery more promising - but only if technological optimism is matched with thoughtful guardrails. AI offers the possibility of faster, more targeted medicines, fresh hope for neglected diseases, and more efficient use of scarce research and development resources.

AI is already reshaping how new medicines are discovered. Instead of relying solely on a long, linear cycle of trial and error, the field is moving toward AI-first pipelines in which models search chemical space, predict failures earlier, and continuously refine drug candidates before they ever reach human testing. Over the next decade, this shift is unlikely to make drug development instantaneous, but it could meaningfully shorten timelines in well-run programs.

Why drug discovery takes so long

Drug development is lengthy and risky by design. From initial idea to approved medicine, the traditional process often takes 10 to 15 years and costs hundreds of millions of dollars, especially once the many failed candidates are taken into account. Early discovery alone - identifying a biological target, screening compounds that interact with it, and optimizing those compounds into a lead candidate - can consume three to six years before any human is dosed.

This slow pace reflects three structural realities.

• Wet-lab research is inherently sequential. Scientists test a hypothesis, wait for results, and only then decide on the next experiment.
• Failure rates are extremely high. Most compounds do not survive preclinical studies or early-stage clinical trials.
• Biology remains hard to predict. Researchers still cannot reliably forecast efficacy and toxicity from first principles, so much of the process depends on learning through expensive experimentation.

Together, these constraints create a slow, high-stakes cycle.

Where AI is already making a difference

AI is not accelerating drug discovery by eliminating steps. It is doing so by making each step more informed, more targeted, and less wasteful.

1. Faster, better target identification

One of the most important advances is in target identification. Traditionally, researchers had to sift through fragmented genetics, omics data, imaging, and published literature to determine which biological pathways mattered most in a disease.

AI models can now integrate these sources at scale and prioritize targets that best explain disease biology. This does not guarantee that a target is correct, but it improves the odds that early research effort is focused on the most promising biology.

2. Searching chemical space in silico

Historically, high-throughput screening required testing vast libraries of compounds in physical assays, followed by slow cycles of chemical refinement.

Deep learning has changed that equation. Generative models can design new molecules from scratch and screen billions of candidates virtually against predicted properties such as binding affinity, solubility, metabolism, and toxicity - long before they reach the bench.

Some companies, including Insilico Medicine and Exscientia, have reported discovery timelines compressed from the conventional three to six years to roughly 11 to 18 months in selected programs. These examples are still early and should not be treated as universal, but they illustrate what an AI-accelerated discovery cycle can look like.

3. Foundation models for biology

A newer wave of innovation is being driven by foundation models trained on large biological datasets, including DNA and protein sequences, small molecules, cellular images, and gene expression profiles.

These models allow researchers to ask more sophisticated questions: not only whether a molecule is likely to bind a target, but also how it may affect cellular behavior and what unintended off-target effects might emerge. By connecting tasks that were once scattered across separate tools and workflows, foundation models can reduce handoffs and shorten the path from idea to testable hypothesis.

How much time can AI realistically save?

The most common question is whether AI can cut drug development time in half. The honest answer is: sometimes in parts of the pipeline, but not automatically across the whole process.

The strongest evidence so far suggests that AI delivers the biggest gains in early discovery and time-to-decision. In those areas, it can help teams reject weak targets and poor-quality compounds earlier, reducing the amount of money and time spent pursuing dead ends.

A realistic near-term scenario for well-equipped organizations may look like this:

• Discovery and preclinical work could shrink from roughly five to seven years to around two to four years, especially when better triage prevents weak candidates from entering expensive downstream studies.
• Overall lab-to-patient timelines for selected programs could move from 10 to 15 years toward something closer to six to 10 years, particularly if AI also improves trial design, recruitment, and execution.

The key point is that AI saves time mainly by helping teams make better decisions earlier. The gain is not magic speed. It is better judgment at scale.

Beyond the lab: AI in clinical development

Discussions about AI and drug discovery often stop at the preclinical stage, even though clinical trials account for much of the time and cost of bringing a medicine to market.

Here too, AI is becoming a force multiplier. Models trained on real-world data and past trial records can:

• Identify where eligible patients are located and which trial sites are most likely to recruit effectively.
• Match patients to complex eligibility criteria using electronic health records, biomarkers, and genomic data.
• Simulate alternative trial designs to estimate probabilities of success and optimize sample sizes.

Used well, these tools can shorten recruitment timelines, reduce underpowered studies, and improve the chances that a trial answers its questions the first time. None of this removes the need for human oversight or ethical review, but it can reduce some of the most time-consuming friction in the clinical process.

The next frontier: AI-first pipelines and in silico trials

Looking ahead, three developments are likely to shape the future of AI-enabled drug discovery.

1. Fully integrated AI-first pipelines

Today, many organizations use AI tactically - for target ranking here, virtual screening there, and trial design somewhere else. The next step is a truly integrated AI-first pipeline, where models support the entire process from data ingestion to candidate nomination.

In that world, AI will not just make existing steps faster. It will change the order and logic of the workflow itself. Comprehensive in silico profiling may happen before wet-lab work begins, and experiments may be designed automatically to maximize information gained from every assay. That kind of redesign could have a greater effect on timelines than simply speeding up isolated tasks.

2. Digital twins and in silico trials

Another promising frontier is the development of digital twins - computational models that simulate individual patients or whole populations.

In principle, these systems could support:

• Virtual dose-finding before first-in-human studies.
• Simulation of subgroup responses to a candidate therapy.
• Rapid testing of alternative trial designs and endpoints.

In the medium term, in silico trials are more likely to complement conventional trials than replace them. Even so, they could significantly shorten the iteration cycle between protocol design and execution, reducing both cost and delay.

3. Learning across portfolios

As companies build richer AI-annotated records of what succeeds and fails, they can train higher-level models to estimate the probability of technical and regulatory success across different targets, modalities, trial designs, and patient segments.

This kind of portfolio intelligence can improve capital allocation. The earlier weak programs are terminated, the less time and money are locked into projects that were unlikely to succeed.

Why acceleration is not automatic

It is tempting to assume that once the models improve, timelines will fall everywhere. That is unlikely.

Several constraints remain.

• Data quality and bias are still major bottlenecks. Many AI systems are trained on narrow, proprietary, or unrepresentative datasets, which makes their predictions fragile when applied to new diseases or populations.
• Regulation is still evolving. Agencies are developing guidance on AI-generated molecules, adaptive trials, and continuously learning systems, but uncertainty can slow adoption.
• Infrastructure is uneven. The most dramatic savings are most likely in organizations with strong data platforms, digital workflows, and high-level AI talent. Smaller biotech firms and many public-sector institutions may not yet have that capacity.

In other words, AI can accelerate discovery, but only when the surrounding scientific and organizational systems are ready to use it well.

What this means for global health

For global health, the central question is whether AI-accelerated discovery can help address diseases that market incentives have long neglected - tropical diseases, region-specific pathogens, and conditions concentrated in lower-income settings.

If AI can reduce the cost and time needed to move from target to proof of concept, then smaller and less commercially attractive drug programs may become more viable. Foundation models could also be fine-tuned on regional data, helping researchers design candidates that better reflect local genetics, co-morbidities, and pathogen variation.

But that outcome is not guaranteed. It will depend on whether high-quality datasets and core AI models are treated as shared infrastructure rather than purely proprietary assets. Public-private partnerships, open-science consortia, and mission-driven funders will be essential if these tools are to serve high-burden, low-profit diseases as well as large commercial markets.

A practical way to think about the future

The most grounded way to think about AI in drug discovery is not as a magic button that produces drugs on demand. It is better understood as a co-pilot across the pipeline - constantly proposing, ranking, and stress-testing hypotheses while human teams remain responsible for judgment, ethics, and strategy.

Under that model, acceleration comes from a compounding effect: fewer weak targets carried forward, fewer poor candidates entering animal and human studies, smarter clinical trials, and better portfolio decisions. The result is a pipeline that still respects scientific and ethical standards, but wastes far less time on the wrong questions.

For patients waiting for new therapies - and for communities whose health needs have long been overlooked - that kind of acceleration could be transformative, provided it is deployed in the service of equity as well as efficiency.

References

1. Fu, C., Chen, Q., and Chen, Q. "The Future of Pharmaceuticals: Artificial Intelligence in Drug Discovery and Development." Acta Pharmaceutica Sinica B (2025).
   

2. From Lab to Clinic: How Artificial Intelligence (AI) Is Reshaping Drug Discovery Timelines and Industry Outcomes. PubMed Central (PMC).
   

3. Foundation Models in Drug Discovery: Phenomenal Growth Today, Transformative Potential Tomorrow? Drug Discovery Today (2025).